• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4: Bain Linda converted options into 15,226 shares and sold $6,753 worth of shares (4,934 units at $1.37), increasing direct ownership by 330% to 13,412 units to cover taxes

    2/21/23 4:32:09 PM ET
    $CDAK
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $CDAK alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
    1. Name and Address of Reporting Person*
    Bain Linda

    (Last) (First) (Middle)
    C/O CODIAK BIOSCIENCES, INC.
    35 CAMBRIDGEPARK DRIVE, SUITE 500

    (Street)
    CAMBRIDGE MA 02140

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Codiak BioSciences, Inc. [ CDAK ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Financial Officer
    3. Date of Earliest Transaction (Month/Day/Year)
    08/16/2022
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 08/16/2022 M 7,613 A (1) 10,733 D
    Common Stock 08/17/2022 S(2) 2,364 D $2.2129 8,369 D
    Common Stock 02/16/2023 M 7,613 A (1) 15,982 D
    Common Stock 02/17/2023 S(2) 2,570 D $0.5922 13,412 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Restricted Stock Units (3) 08/16/2022 M 7,613 (4) (4) Common Stock 7,613 $0.00 22,837 D
    Restricted Stock Units (3) 02/16/2023 M 7,613 (4) (4) Common Stock 7,613 $0.00 15,224 D
    Explanation of Responses:
    1. Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.
    2. The sales reported in this Form 4 were effected to cover tax withholding obligations in connection with the vesting of RSUs pursuant to a "sell to cover" provision included in the RSU Agreement.
    3. Each RSU represents a contingent right to receive one share of common stock.
    4. On February 16, 2022, the reporting person was granted 30,450 RSUs, vesting in four equal installments every six months beginning on the six month anniversary of the grant date.
    Remarks:
    /s/ Yalonda Howze, Attorney-in-Fact for Linda Bain 02/21/2023
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $CDAK alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CDAK

    DatePrice TargetRatingAnalyst
    2/22/2022$34.00 → $24.00Outperform
    Wedbush
    2/11/2022$19.00Buy
    Goldman Sachs
    More analyst ratings

    $CDAK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Howze Yalonda

      4 - Codiak BioSciences, Inc. (0001659352) (Issuer)

      3/30/23 6:01:07 PM ET
      $CDAK
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 4 filed by Sathyanarayanan Sriram

      4 - Codiak BioSciences, Inc. (0001659352) (Issuer)

      3/30/23 5:19:21 PM ET
      $CDAK
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 4 filed by Konstantinov Konstantin

      4 - Codiak BioSciences, Inc. (0001659352) (Issuer)

      3/30/23 5:13:35 PM ET
      $CDAK
      Medicinal Chemicals and Botanical Products
      Health Care

    $CDAK
    Leadership Updates

    Live Leadership Updates

    See more
    • Codiak Appoints David Mauro, M.D., Ph.D., as Chief Medical Officer

      CAMBRIDGE, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (NASDAQ:CDAK), a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a new class of medicines, today announced the appointment of David Mauro, M.D., Ph.D., a veteran oncology and immunotherapy drug developer, as Chief Medical Officer. Dr. Mauro will provide leadership and expertise for Codiak's pipeline of clinical development programs through early-stage trials to global regulatory submissions and joins the company's Executive Leadership Team reporting to Douglas E. Williams, Ph.D., President and CEO. "We have been fortunate to work with David since late last year

      5/2/22 9:00:00 AM ET
      $CDAK
      Medicinal Chemicals and Botanical Products
      Health Care
    • Flagship Pioneering Bolsters Executive Team with Appointment of Michelle C. Werner as CEO-Partner and CEO of Alltrna

      Werner Brings More Than Two Decades of Pharmaceutical Leadership to the Role CAMBRIDGE, Mass., April 11, 2022 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today announced it has strengthened its executive leadership team with the appointment of Michelle C. Werner to the dual role of CEO-Partner of Flagship Pioneering and Chief Executive Officer of Alltrna. Werner brings to Flagship significant experience as a global pharmaceutical leader spanning both Commercial and Research and Development (R&D) responsibilities.  Werner most recently served as Wo

      4/11/22 6:00:00 AM ET
      $AXLA
      $CDAK
      $DNLI
      $EVLO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Medicinal Chemicals and Botanical Products
      Biotechnology: Pharmaceutical Preparations
    • Alltrna Appoints Rare Disease Clinical Research Expert, Dr. Anne Pariser, as Vice President, Medical and Regulatory Affairs

      CAMBRIDGE, Mass., Feb. 28, 2022 /PRNewswire/ -- Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced the appointment of Anne Pariser, M.D., as Vice President, Medical and Regulatory Affairs. Prior to joining Alltrna, Dr. Pariser was the Director of the Office of Rare Diseases Research (ORDR) at the National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH), whose mission is to advance rare diseases research through a variety of research programs. Prior to ORDR, she worked at the U.S. Food and Drug Administration (FDA) Center for

      2/28/22 9:00:00 AM ET
      $AXLA
      $CDAK
      $DNLI
      $EVLO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Medicinal Chemicals and Botanical Products
      Biotechnology: Pharmaceutical Preparations